BI-RADS 3审计值。

Prithwijit Roychowdhury, Gopal R Vijayaraghavan, John Roubil, Imani M Williams, Efaza Siddiqui, Srinivasan Vedantham
{"title":"BI-RADS 3审计值。","authors":"Prithwijit Roychowdhury,&nbsp;Gopal R Vijayaraghavan,&nbsp;John Roubil,&nbsp;Imani M Williams,&nbsp;Efaza Siddiqui,&nbsp;Srinivasan Vedantham","doi":"10.26717/BJSTR.2022.41.006668","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>BI-RADS 3 is an established assessment category in which the probability of malignancy is equal to or less than 2%. However, monitoring adherence to imaging criteria can be challenging and there are few established benchmarks for auditing BI-RADS 3 assignments. In this study, we explore some parameters that could serve as useful tools for quality control and clinical practice management.</p><p><strong>Materials and methods: </strong>This retrospective study covered a 4-year period (Jan 2014-Dec 2017) and included all women over 40 years who were recalled from a screening exam and had an initial assignment of BI-RADS 3 (probably benign) category after diagnostic workup. A follow-up period of 2 years following the assignment of BI-RADS 3 was used for quantitative quality control metrics.</p><p><strong>Results: </strong>Among 135,765 screening exams, 13,453 were recalled and 1,037 BI-RADS 3 cases met inclusion criteria. The follow-up rate at 24 months was 86.7%. The upgrade rate was 7.4% (77/1,037) [CI: 5.9-9.2%] and the PPV3 was 33.8% (26/77) [CI: 23.4-45.5%]. The cancer yield was 2.51% (26/1,037) [CI: 1.64-3.65%] and did not differ (p=0. 243) from the 2% probability of malignancy. The initial BI-RADS3 per screening exam and per recall from screening were 0.76% (1,037/135,765) [CI: 0.72-0.81%] and 7.7% (1,037/13,453) [CI: 7.26-8.17%], respectively.</p><p><strong>Conclusion: </strong>Regular audit of BIRADS 3 metrics has the potential to provide additional insights for clinical practice management. Data from varied clinical settings with input from an expert committee could help establish benchmarks for these metrics.</p>","PeriodicalId":9035,"journal":{"name":"Biomedical Journal of Scientific & Technical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983005/pdf/nihms-1790042.pdf","citationCount":"2","resultStr":"{\"title\":\"Value of BI-RADS 3 Audits.\",\"authors\":\"Prithwijit Roychowdhury,&nbsp;Gopal R Vijayaraghavan,&nbsp;John Roubil,&nbsp;Imani M Williams,&nbsp;Efaza Siddiqui,&nbsp;Srinivasan Vedantham\",\"doi\":\"10.26717/BJSTR.2022.41.006668\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>BI-RADS 3 is an established assessment category in which the probability of malignancy is equal to or less than 2%. However, monitoring adherence to imaging criteria can be challenging and there are few established benchmarks for auditing BI-RADS 3 assignments. In this study, we explore some parameters that could serve as useful tools for quality control and clinical practice management.</p><p><strong>Materials and methods: </strong>This retrospective study covered a 4-year period (Jan 2014-Dec 2017) and included all women over 40 years who were recalled from a screening exam and had an initial assignment of BI-RADS 3 (probably benign) category after diagnostic workup. A follow-up period of 2 years following the assignment of BI-RADS 3 was used for quantitative quality control metrics.</p><p><strong>Results: </strong>Among 135,765 screening exams, 13,453 were recalled and 1,037 BI-RADS 3 cases met inclusion criteria. The follow-up rate at 24 months was 86.7%. The upgrade rate was 7.4% (77/1,037) [CI: 5.9-9.2%] and the PPV3 was 33.8% (26/77) [CI: 23.4-45.5%]. The cancer yield was 2.51% (26/1,037) [CI: 1.64-3.65%] and did not differ (p=0. 243) from the 2% probability of malignancy. The initial BI-RADS3 per screening exam and per recall from screening were 0.76% (1,037/135,765) [CI: 0.72-0.81%] and 7.7% (1,037/13,453) [CI: 7.26-8.17%], respectively.</p><p><strong>Conclusion: </strong>Regular audit of BIRADS 3 metrics has the potential to provide additional insights for clinical practice management. Data from varied clinical settings with input from an expert committee could help establish benchmarks for these metrics.</p>\",\"PeriodicalId\":9035,\"journal\":{\"name\":\"Biomedical Journal of Scientific & Technical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983005/pdf/nihms-1790042.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Journal of Scientific & Technical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26717/BJSTR.2022.41.006668\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Journal of Scientific & Technical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26717/BJSTR.2022.41.006668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

目的:BI-RADS 3是一个既定的评估类别,其中恶性肿瘤的概率等于或小于2%。然而,监测成像标准的依从性是具有挑战性的,并且很少有既定的基准来审计BI-RADS 3任务。在本研究中,我们探讨了一些参数可以作为质量控制和临床实践管理的有用工具。材料和方法:这项回顾性研究涵盖了4年(2014年1月- 2017年12月),包括所有40岁以上的女性,她们从筛查检查中被召回,在诊断检查后被初始分配为BI-RADS 3(可能是良性的)类别。在BI-RADS 3分配后的2年随访期用于定量质量控制指标。结果:135,765例筛查检查中,召回13,453例,1037例BI-RADS 3符合纳入标准。24个月随访率为86.7%。升级率为7.4% (77/ 1037)[CI: 5.9-9.2%], PPV3为33.8% (26/77)[CI: 23.4-45.5%]。两组的肿瘤发生率为2.51% (26/ 1037)[CI: 1.64-3.65%],差异无统计学意义(p= 0.05)。243)从2%的恶性概率。每次筛查检查和每次筛查召回的初始BI-RADS3分别为0.76% (1,037/135,765)[CI: 0.72-0.81%]和7.7% (1,037/13,453)[CI: 7.26-8.17%]。结论:定期审核BIRADS 3指标有可能为临床实践管理提供额外的见解。来自不同临床环境的数据以及专家委员会的输入可以帮助建立这些指标的基准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Value of BI-RADS 3 Audits.

Objectives: BI-RADS 3 is an established assessment category in which the probability of malignancy is equal to or less than 2%. However, monitoring adherence to imaging criteria can be challenging and there are few established benchmarks for auditing BI-RADS 3 assignments. In this study, we explore some parameters that could serve as useful tools for quality control and clinical practice management.

Materials and methods: This retrospective study covered a 4-year period (Jan 2014-Dec 2017) and included all women over 40 years who were recalled from a screening exam and had an initial assignment of BI-RADS 3 (probably benign) category after diagnostic workup. A follow-up period of 2 years following the assignment of BI-RADS 3 was used for quantitative quality control metrics.

Results: Among 135,765 screening exams, 13,453 were recalled and 1,037 BI-RADS 3 cases met inclusion criteria. The follow-up rate at 24 months was 86.7%. The upgrade rate was 7.4% (77/1,037) [CI: 5.9-9.2%] and the PPV3 was 33.8% (26/77) [CI: 23.4-45.5%]. The cancer yield was 2.51% (26/1,037) [CI: 1.64-3.65%] and did not differ (p=0. 243) from the 2% probability of malignancy. The initial BI-RADS3 per screening exam and per recall from screening were 0.76% (1,037/135,765) [CI: 0.72-0.81%] and 7.7% (1,037/13,453) [CI: 7.26-8.17%], respectively.

Conclusion: Regular audit of BIRADS 3 metrics has the potential to provide additional insights for clinical practice management. Data from varied clinical settings with input from an expert committee could help establish benchmarks for these metrics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Immunomodulatory Strategies for Spinal Cord Injury. A Case of Thoracic Disc Herniation Effectively Treated with Interventional Radiology Computed Tomography- Guided Percutaneous Endoscopic Radiofrequency Annuloplasty Using a Disc-Fx® COVID-19 and Human Immune System Responses Stress Prevalence in College Students During COVID-19 Pandemics: Evidence from Economics Undergraduates in a Developing Country Pore Characterization of Alumina Short Fiber Using Small Angle X-Ray Scattering Technique
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1